

19 June 2020


ASX Announcement

Notification of Lapse of Unlisted Options

19 June 2020 – Race Oncology Limited (ASX: RAC) confirms the lapse of the 750,000 unlisted options exercisable at \$0.32 and expiring on 16 May 2023 due to the vesting conditions having not been met.

The total number of unlisted options on issue following the expiry is as follows:

Expiry Date	Exercise Price	Number
1 July 2021	\$0.25	9,000,000
1 August 2021	\$0.256	135,000
31 August 2021	\$0.099	10,854,542
25 November 2021	\$0.25	3,000,000
27 November 2021	\$0.23	2,000,000
12 March 2022	\$0.45	1,500,000
1 April 2022	\$0.25	1,500,000
8 May 2022	\$0.25	100,000
25 November 2022	\$0.19	2,500,000
1 October 2023	\$0.12	420,000
21 January 2024	\$0.12	420,000
17 February 2024	\$0.49	2,400,000
12 March 2024	\$0.135	100,000
31 May 2024	\$0.085	840,000
5 December 2024	\$0.18	840,000
23 January 2025	\$0.275	2,400,000
		38,009,542



Peter Webse
Company Secretary

Release authorised by:

John Cullity – Executive Chairman
john@biosynergypartners.com

Media contact:

Henry Jordan
+61 431 271 538
henry.jordan@sdir.com.au

About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called Bisantrone. RAC has compelling clinical data for Bisantrone in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.